Patents Assigned to Novartis Vaccines and Diagnostics GmbH
-
Patent number: 8632505Abstract: The invention provides a syringe accessory device for adjustment of a predefined partial syringe dosage comprises a recess (10) for receiving a syringe body (14). Additionally, within a single portion (12) a slot (16) is located. Within the slot (16) a syringe flange (18) or finger grip can be held. To obtain a predefined dosage of liquid within the chamber of the syringe body (14), a plunger (26) is pressed in the chamber (14) in the direction of the arrow (38) until the plunger head (44) contacts a stopping means (24) whereby the stopping means is performed by a stopping surface (24) of the single portion (12). The invention further provides a kit comprising said syringe accessory device and its use for adjusting defined liquid dosages in syringes.Type: GrantFiled: March 15, 2006Date of Patent: January 21, 2014Assignee: Novartis Vaccines & Diagnostics, GmbHInventor: Mathias Fibi
-
Patent number: 8444992Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: GrantFiled: September 4, 2012Date of Patent: May 21, 2013Assignee: Novartis Vaccines and Diagnostics GmbHInventor: Astrid Borkowski
-
Publication number: 20130059364Abstract: The present invention relates to a culture medium for disperse mycobacteria comprising at least one detergent and an antifoam agent, whereby said antifoam agent is a member of the silicone family. In addition, the invention provides for methods for the activation of dipressed mycobacteria, for obtaining a standardized mycobyterial culture or for the production of (a), purified protein derivates(s) (PDD) which comprise the cultivation of mycobacteria in the active medium disclosed herein. Furthermore, the use of standardized mycobacterial cultures obtained by the method of the invention for the preparation of pharmaceutical or diagnostic compositions is described.Type: ApplicationFiled: July 3, 2012Publication date: March 7, 2013Applicant: Novartis Vaccines and Diagnostics GmbHInventors: Guido Dietrich, Erika Hundt, Heinz Weber
-
Patent number: 8361477Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: GrantFiled: August 29, 2011Date of Patent: January 29, 2013Assignee: Novartis Vaccines and Diagnostics GmbHInventor: Astrid Borkowski
-
Publication number: 20110311574Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: ApplicationFiled: August 29, 2011Publication date: December 22, 2011Applicant: Novartis Vaccines and Diagnostics GmBHInventor: ASTRID BORKOWSKI
-
Patent number: 8007807Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: GrantFiled: September 1, 2006Date of Patent: August 30, 2011Assignee: Novartis Vaccines and Diagnostics GmbHInventor: Astrid Borkowski
-
Publication number: 20110165192Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane.Type: ApplicationFiled: December 3, 2010Publication date: July 7, 2011Applicant: Novartis Vaccines and Diagnostics, GmbH & Co. KGInventors: Harald Rueckl, Hanno Scheffczik, Barbara Santry
-
Publication number: 20110162982Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.Type: ApplicationFiled: December 3, 2010Publication date: July 7, 2011Applicant: Novartis Vaccines and Diagnostic, GmbH & Co. KGInventors: Gottfried Kraus, Robert Eskes
-
Publication number: 20110165193Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane.Type: ApplicationFiled: December 3, 2010Publication date: July 7, 2011Applicant: Novartis Vaccines and Diagnostics, GmbH & Co. KGInventors: Harald Rueckl, Hanno Scheffczik
-
Publication number: 20110027314Abstract: An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2 OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins.Type: ApplicationFiled: January 26, 2007Publication date: February 3, 2011Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KGInventors: Michael Broeker, Holger Kost
-
Publication number: 20100183671Abstract: An influenza vaccine that lacks at least three of a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components.Type: ApplicationFiled: June 27, 2008Publication date: July 22, 2010Applicant: Novartis Vaccines & Diagnostics GmbH & Co., KGInventors: Jens-Peter Gregersen, Holger Luebben, Juergen Vorlop
-
Publication number: 20090304729Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.Type: ApplicationFiled: November 1, 2006Publication date: December 10, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KGInventors: Jens-Peter Gregersen, Holger Kost
-
Publication number: 20080274141Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof.Type: ApplicationFiled: June 26, 2008Publication date: November 6, 2008Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KGInventors: Albrecht Groner, Jurgen Vorlop